NCT04496479 Allogenic Hepatocyte Transplantation Into Periduodenal Lymph Nodes
| NCT ID | NCT04496479 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | LyGenesis, Inc. |
| Condition | End Stage Liver Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 12 participants |
| Start Date | 2022-03-11 |
| Primary Completion | 2027-08-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 12 participants in total. It began in 2022-03-11 with a primary completion date of 2027-08-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This Phase 2a clinical trial is a dose escalation study of the safety, tolerability, and efficacy of hepatocyte transplantation into lymph nodes via endoscopic ultrasound among subjects with end-stage liver disease.
Eligibility Criteria
Inclusion Criteria: 1. Have read, understood, and signed the informed consent form (ICF). 2. Adults of either gender and ages 18 to 70 years old with a diagnosis of ESLD due to alcohol, chronic hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infections, autoimmune hepatitis, primary sclerosis cholangitis, primary biliary cirrhosis (cholangitis), cirrhosis as the result of Wilson disease, hemochromatosis, sarcoidosis and alpha 1 antitrypsin deficiency, cryptogenic cirrhosis, and nonalcoholic steatohepatitis cirrhosis with a MELD-Na score \>10 and \<25 at screening. 3. Subjects must have a body mass index (BMI) \<35. 4. Subjects with HCV associated ESLD must have been treated and demonstrate 24 weeks of negative HCV ribonucleic acid (RNA). 5. Subjects with HBV must be on stable therapy for 6 months and have HBV deoxyribonucleic acid \<500 c/mL. 6. Women of childbearing potential (WOCBP) or sexual partners of male subjects who are WOCBP must be able and willing to use at least 1 highly effective method of contraception during the study and for 1 month after the last study visit. A female subject is considered to be a WOCBP after menarche and until she is in a postmenopausal state for 12 months or otherwise permanently sterile (for which acceptable methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy; HMA, 2014). For the definition and list of highly effective methods of contraception, see Appendix 1. 7. Has stable control of portal hypertension and upper gastrointestinal bleeding with medical therapy and/or endoscopic therapy. 8. If the subject has undergone a TIPS procedure for the clinical management of portal hypertension, they must be stable after the successful TIPS procedure, and not experiencing serious complications from the TIPS procedure itself (e.g., infection and intractable hepatic encephalopathy). 9. Has blood urea nitrogen (BUN) \<80 mg/dL. 10. Has an estimated glomerular filtration rate (eGFR) ≥45 mL/min/1.73 m2. 11. Agrees to avoid alcohol consumption during the study. 12. Is willing and able to comply with all requirements of the study protocol. Exclusion Criteria: 1. Has primary hepatic neoplasms (hepatocellular carcinoma and cholangiocarcinoma). 2. Has active and/or uncontrolled severe infections requiring hospitalization and prolonged antimicrobial therapy. 3. Has severe coagulopathy (international normalized ratio \[INR\] \>2, and/or platelet count \<50,000/μL). 4. Has psychiatric and/or social issues that could lead to noncompliance. 5. Has an extrahepatic neoplastic disease requiring active chemotherapy, immunotherapy, and/or surgical resection. 6. Has previously treated neoplastic disease with less than a 2-year cancer free period. 7. Pregnant and lactating women should not be in the study. 8. Known hypersensitivity to human serum albumin. 9. Subjects with uncontrolled hypertension (defined as a diastolic blood pressure of 110 mmHg or higher). 10. Has recurrent/intractable ascites refractory to diuretics and requiring periodic large volume paracentesis. 11. Has primary alcoholic liver disease and has not demonstrated abstinence for at least 24 weeks (6 months) prior to enrollment while attending mandatory rehab programs (e.g., Alcoholics Anonymous) and psychotherapy. 12. Has grade 3 esophageal varices requiring the continuous use of propranolol and cannot afford to have this medication withheld and/or discontinued. 13. Has a Child-Turcotte-Pugh (CTP) Class of C. 14. Is receiving or plans to receive treatment with another investigational product or device.
Contact & Investigator
Paulo Fontes, MD
STUDY CHAIR
LyGenesis, Inc.
Frequently Asked Questions
Who can join the NCT04496479 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying End Stage Liver Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT04496479 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT04496479 currently recruiting?
Yes, NCT04496479 is actively recruiting participants. Contact the research team at fontesp@lygenesis.com for enrollment information.
Where is the NCT04496479 trial being conducted?
This trial is being conducted at Boston, United States, Houston, United States.
Who is sponsoring the NCT04496479 clinical trial?
NCT04496479 is sponsored by LyGenesis, Inc.. The principal investigator is Paulo Fontes, MD at LyGenesis, Inc.. The trial plans to enroll 12 participants.